1 week Ago By Defense World Staff
Corebridge Financial Inc. lowered its stake in shares of AxoGen, Inc. (NASDAQ:AXGN – Free Report) by 7.
0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,081 shares of the medical equipment provider’s stock after selling 1,591 shares during the quarter. Corebridge Financial Inc.
’s holdings in AxoGen were worth $347,000 at the end of the most recent reporting period. A number of other hedge funds have also recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc.
grew its holdings in shares of AxoGen by 8.6% during the 3rd quarter. Charles Schwab Investment Management Inc.
now owns 363,764 shares of the medical equipment provider’s stock worth $5,100,000 after purchasing an additional 28,659 shares in the last quarter. FMR LLC lifted its position in AxoGen by 743.1% during the third quarter.
FMR LLC now owns 178,957 shares of the medical equipment provider’s stock worth $2,509,000 after purchasing an additional 157,730 shares during the period. BNP Paribas Financial Markets grew its stake in AxoGen by 238.6% during the third quarter.
BNP Paribas Financial Markets now owns 12,284 shares of the medical equipment provider’s stock worth $172,000 after buying an additional 8,656 shares in the last quarter. Verition Fund Management LLC increased its holdings in AxoGen by 41.0% in the 3rd quarter.
Verition Fund Management LLC now owns 40,860 shares of the medical equipment provider’s stock valued at $573,000 after buying an additional 11,874 shares during the period. Finally, Point72 Asset Management L.P.
acquired a new position in shares of AxoGen in the 3rd quarter valued at approximately $240,000. Institutional investors own 80.29% of the company’s stock.
Insider Buying and Selling at AxoGenIn related news, insider Erick Wayne Devinney sold 15,111 shares of the business’s stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $17.50, for a total value of $264,442.
50. Following the transaction, the insider now directly owns 217,762 shares of the company’s stock, valued at approximately $3,810,835. The trade was a 6.
49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Amy Mcbride Wendell sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd.
The stock was sold at an average price of $20.02, for a total transaction of $100,100.00.
Following the sale, the director now owns 97,899 shares of the company’s stock, valued at approximately $1,959,937.98. The trade was a 4.
86 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.
00% of the company’s stock. AxoGen Stock PerformanceNASDAQ AXGN opened at $16.76 on Thursday.
The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.
47. The company has a fifty day moving average price of $17.98 and a 200-day moving average price of $16.
03. AxoGen, Inc. has a 1 year low of $5.
55 and a 1 year high of $21.00. The firm has a market cap of $743.
21 million, a price-to-earnings ratio of -52.38 and a beta of 1.00.
Analysts Set New Price TargetsAXGN has been the topic of several research analyst reports. Lake Street Capital began coverage on AxoGen in a research note on Monday, March 17th. They issued a “buy” rating and a $30.
00 price objective on the stock. Canaccord Genuity Group raised their price target on shares of AxoGen from $22.00 to $26.
00 and gave the stock a “buy” rating in a report on Wednesday, February 26th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $24.00 target price on shares of AxoGen in a research note on Wednesday, March 5th.
Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $22.60.
Read Our Latest Stock Report on AXGNAbout AxoGen (Free Report)AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.Further ReadingFive stocks we like better than AxoGenTrading Stocks: RSI and Why it’s UsefulQuantum Computing: The $6.
5 Billion Opportunity You Can’t IgnoreHow to trade using analyst ratingsAre Tariffs Threatening Disney’s Comeback Story?What is Short Interest? How to Use ItIs Alphabet a Generational Buying Opportunity at These Levels?.
